Sign in Subscribe
Cancer research

Breakthrough in Liver Cancer Research: Novel Therapies Emerges Through Computational Pipeline

Strategic Insights

— 1 min read

Researchers from the Pharmaceutical Sciences Research Center have made significant progress in the fight against liver cancer by developing a robust computational pipeline that identifies promising new anti-liver-cancer agents. The study focuses on tubulin, a key protein involved in cancer cell proliferation, and utilizes a combination of QSAR, molecular docking, dynamics, and ADME to identify potential candidates. The pipeline's success has been validated through its predictive accuracy and the identification of a top candidate that exhibited exceptional binding affinity at tubulin's colchicine site.

Key Takeaways:

  • The rising incidence of liver cancer highlights the urgent need for novel therapies targeting crucial molecular mediators such as tubulin.
  • The study aims to address this need through a computational pipeline combining QSAR, molecular docking, dynamics, and ADME to identify new promising anti-liver-cancer agents.
  • The pipeline's QSAR model achieved 92.7% predictive accuracy, highlighting HeavyAtomCount and Chi1n as pivotal structural descriptors correlating with anti-proliferative activity in HepG2 cells.
  • Virtual screening enabled the identification of top candidates based on their anti-proliferative potential, with compound 31 exhibiting exceptional binding affinity (-8.684 kcal/mol) at tubulin's colchicine site.
  • ADME profiling confirmed favorable pharmacokinetics and low BBB permeability for lead candidates, and molecular dynamics (MD) simulations further validated compound 31's stability.
  • The study established a computationally rigorous pipeline for anticancer drug discovery, offering phenanthrene-based scaffolds as candidates for in vitro testing.
  • The research provides a pipeline for accelerating drug discovery, especially novel anticancer agents, and elucidates structure-activity principles for tubulin inhibition.

Statistics:

  • The pipeline's QSAR model achieved 92.7% predictive accuracy.
  • Compound 31 exhibited exceptional binding affinity (-8.684 kcal/mol) at tubulin's colchicine site.
  • ADME profiling confirmed favorable pharmacokinetics and low BBB permeability for lead candidates.
  • Molecular dynamics (MD) simulations lasted 200 ns and validated compound 31's stability.
  • The study has been peer-reviewed and published in the journal Talanta.

Sources:

  • Talanta (Elsevier, 2025) - "Phenanthrenes as anti-liver cancer agents: A computational pipeline to tubulin inhibition."
  • Pharmaceutical Sciences Research Center - http://www.crsps.com
  • Saida Meliani (Pharmaceutical Sciences Research Center CRSP, Zone of Activity ZAM, Nouvelle Ville Ali Mendjeli, Constantine, Algeria) - Email: [email address]

Read more